Malignant Potentially Fatal Asthma: Achievement of Remission and the Application of an Asthma Severity Index
Patients fulfilling diagnostic criteria for malignant potentially fatal asthma require aggressive involvement by the physician to prevent avoidable fatalities from asthma. Efforts to overcome barriers to treatment caused by noncompliance are critical to successful care. This report reviews five patients with malignant potentially fatal asthma in remission, in whom noncompliance played the major role in preventing control of asthma.
Through patient confrontation and the monitoring of serum concentrations of prednisone and its metabolite prednisolone, noncompliance may be addressed. Psychiatric referral may also be of benefit, if accepted by the patient and family. Use of injectable methylprednisolone may be a necessary alternative to prevent life-threatening complications of asthma. In all patients, keeping medical regimens as simple as possible is advocated, with the use of the lowest doses of medication necessary to maintain the control of symptoms, and the prevention of morbidity and mortality. An asthma severity index for the illustration of longitudinal disease severity is applied to these patients.
Through patient confrontation and the monitoring of serum concentrations of prednisone and its metabolite prednisolone, noncompliance may be addressed. Psychiatric referral may also be of benefit, if accepted by the patient and family. Use of injectable methylprednisolone may be a necessary alternative to prevent life-threatening complications of asthma. In all patients, keeping medical regimens as simple as possible is advocated, with the use of the lowest doses of medication necessary to maintain the control of symptoms, and the prevention of morbidity and mortality. An asthma severity index for the illustration of longitudinal disease severity is applied to these patients.
Document Type: Research Article
Publication date: 01 September 1993
- Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.
The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma and by having the potential to directly impact the quality of patient care. AAP welcomes the submission of original works including peer-reviewed original research and clinical trial results. Additionally, as the official journal of the Eastern Allergy Conference (EAC), AAP will publish content from EAC poster sessions as well as review articles derived from EAC lectures.
Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.
Articles marked "F" offer free full text for personal noncommercial use only.
The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service. - Editorial Board
- Information for Authors
- Submit a Paper
- Information for Advertisers
- Reprint Requests
- Commercial level: Permission to use content
- www.JFoodAllergy.com
- Ingenta Connect is not responsible for the content or availability of external websites
Receive new issue alert- Access Key
- Free content
- Partial Free content
- New content
- Open access content
- Partial Open access content
- Subscribed content
- Partial Subscribed content
- Free trial content